Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Featured trial
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly with Routine Infant Vaccines to Healthy Infants

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when

vaccination
pneumococcal
pcv13 vaccine
conjugate vaccine
  • 0 views
  • 24 Jun, 2022
  • 1 location
A Phase II Randomized, Observer-Blind, Placebo-Controlled Study, to Assess the Efficacy of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) in Preventing Gonococcal Infection

This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years

Accepts healthy volunteers
  • 107 views
  • 16 Sep, 2022
  • 7 locations
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when

Accepts healthy volunteers
vaccination
bexsero
varivax
pneumococcal
  • 268 views
  • 17 Sep, 2022
  • 31 locations
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

only) To describe the safety profile of the SP MenB vaccine formulations, Bexsero Vaccine and Trumenba Vaccine in healthy adults, and adolescents; To describe the safety

Accepts healthy volunteers
  • 50 views
  • 27 Jul, 2022
  • 21 locations
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

only) To describe the safety profile of the SP MenB vaccine formulations, Bexsero Vaccine and Trumenba Vaccine in healthy adults, and adolescents; To describe the safety

Accepts healthy volunteers
  • 29 views
  • 29 Jul, 2022
  • 21 locations
Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

This is a double-blind randomized controlled trial to test whether the group B meningitis vaccine 4 component Neisseria meningitidis serogroup B vaccine (BEXSEROTM) (4C-MenB), trade name Bexsero

Accepts healthy volunteers
  • 10 views
  • 05 Jun, 2022
  • 1 location
Mucosal Immune Responses Against Neisseria Gonorrhoeae Following Meningococcal Immunization in Healthy Young Adults

This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40

Accepts healthy volunteers
  • 0 views
  • 18 Sep, 2022
  • 1 location
Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men (GoGoVax)

This is a Phase 3, double-blinded, randomised placebo-controlled, multi-centred trial evaluating the efficacy of the four-component meningococcal B vaccine, 4CMenB (Bexsero®), in the prevention

  • 6 views
  • 26 Apr, 2022
  • 2 locations
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

titer ≥ 1:8) when MenACYW conjugate vaccine is administered concomitantly with Bexsero® in the second year of life compared to when MenACYW conjugate vaccine is given alone The secondary objective is to

Accepts healthy volunteers
meningococcal conjugate
strain
tetanus toxoid
polysaccharide
  • 2 views
  • 27 Jul, 2022
  • 13 locations
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

receiving antiretroviral treatment. Participants are randomized 1:1 to either a two-dose Menveo and Bexsero regimen or a Prevenar13/Pneumovax23 prime-boost regimen at day 0 and day 60 and cross over

  • 0 views
  • 12 May, 2021
  • 1 location